Aortic Stenosis Treatment Market Study by Transcatheter Aortic Valve Replacement, Surgical Aortic Valve Replacement, Balloon Valvuloplasty, Beta Blockers, and Cardiac Glycosides from 2024 to 2034

<p>Worldwide revenue from aortic stenosis treatment solutions is expected to reach <strong>US$ 7.57 billion</strong> in 2024, as revealed in Fact.MR&rsquo;s newly published market report. The global aortic stenosis treatment market has been forecasted to expand at a <strong>CAGR of 9.7%</strong> and climb to a value of <strong>US$ 19.09 billion</strong> by 2034-end.</p><table><thead><tr><th>Report Attribute</th><th>Detail</th></tr></thead><tbody><tr><td>Aortic Stenosis Treatment Market Size (2024E)</td><td>US$ 7.57 Billion</td></tr><tr><td>Forecasted Market Value (2034F)</td><td>US$ 19.09 Billion</td></tr><tr><td>Global Market Growth Rate (2024 to 2034)</td><td>9.7% CAGR</td></tr><tr><td>Market Share of Transcatheter Aortic Valve Replacement Segment (TAVR) (2034F)</td><td>67.9%</td></tr><tr><td>Western Europe Market Share (2034F)</td><td>14.9%</td></tr><tr><td>Canada Market Growth Rate (2024 to 2034)</td><td>13.7% CAGR</td></tr><tr><td>Key Companies Profiled</td><td>Braile Biom&eacute;dica; Edwards Lifesciences Corporation; Thubrikar Aortic Valve; Medtronic Plc; AstraZeneca Plc; Micro Interventional Devices, Inc.; Abbott Laboratories; Meril Life Sciences Pvt. Ltd.; Boston Scientific Corporation; JenaValve Technology, Inc.; LivaNova PLC; CryoLife, Inc.</td></tr></tbody></table><p>Country-wise Insights</p><table><thead><tr><th>Attribute</th><th>United States</th></tr></thead><tbody><tr><td>Market Value (2024E)</td><td>US$ 2.49 Billion</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>11% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 7.05 Billion</td></tr></tbody></table><table><thead><tr><th>Attribute</th><th>India</th></tr></thead><tbody><tr><td>Market Value (2024E)</td><td>US$ 451.7 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>14.5% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 1.75 Billion</td></tr></tbody></table><table><thead><tr><th>Attribute</th><th>Japan</th></tr></thead><tbody><tr><td>Market Value (2024E)</td><td>US$ 332.8 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>3.7% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 477.9 Million</td></tr></tbody></table><p>Category-wise Insights</p><table><thead><tr><th>Attribute</th><th>Transcatheter Aortic Valve Replacement (TAVR)</th></tr></thead><tbody><tr><td>Segment Value (2024E)</td><td>US$ 4.94 Billion</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>10.1% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 12.96 Billion</td></tr></tbody></table><table><thead><tr><th>Attribute</th><th>Hospitals</th></tr></thead><tbody><tr><td>Market Value (2024E)</td><td>US$ 4.56 Billion</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>9.9% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 11.68 Billion</td></tr></tbody></table>

<p>据Fact.MR最新发布的全球市场报告披露，2024年全球主动脉瓣狭窄治疗解决方案的收入预计将达到<strong>757亿美元</strong>。预计全球主动脉瓣狭窄治疗市场将以年复合增长率（CAGR）<strong>9.7%</strong>的速度扩张，并将在2034年末达到价值<strong>1909亿美元</strong>。</p><table><thead><tr><th>报告属性</th><th>详细信息</th></tr></thead><tbody><tr><td>主动脉瓣狭窄治疗市场规模（2024E）</td><td>757亿美元</td></tr><tr><td>预测市场价值（2034F）</td><td>1909亿美元</td></tr><tr><td>全球市场增长率（2024年至2034年）</td><td>9.7% CAGR</td></tr><tr><td>经导管主动脉瓣置换术（TAVR）市场占有率（2034F）</td><td>67.9%</td></tr><tr><td>西欧市场占有率（2034F）</td><td>14.9%</td></tr><tr><td>加拿大市场增长率（2024年至2034年）</td><td>13.7% CAGR</td></tr><tr><td>主要公司简介</td><td>Braile Biomédica; Edwards Lifesciences Corporation; Thubrikar Aortic Valve; Medtronic Plc; AstraZeneca Plc; Micro Interventional Devices, Inc.; Abbott Laboratories; Meril Life Sciences Pvt. Ltd.; Boston Scientific Corporation; JenaValve Technology, Inc.; LivaNova PLC; CryoLife, Inc.</td></tr></tbody></table><p>各国市场洞察</p><table><thead><tr><th>属性</th><th>美国</th></tr></thead><tbody><tr><td>市场价值（2024E）</td><td>24.9亿美元</td></tr><tr><td>增长率（2024年至2034年）</td><td>11% CAGR</td></tr><tr><td>预测价值（2034F）</td><td>70.5亿美元</td></tr></tbody></table><table><thead><tr><th>属性</th><th>印度</th></tr></thead><tbody><tr><td>市场价值（2024E）</td><td>4.51亿美元</td></tr><tr><td>增长率（2024年至2034年）</td><td>14.5% CAGR</td></tr><tr><td>预测价值（2034F）</td><td>17.5亿美元</td></tr></tbody></table><table><thead><tr><th>属性</th><th>日本</th></tr></thead><tbody><tr><td>市场价值（2024E）</td><td>3.32亿美元</td></tr><tr><td>增长率（2024年至2034年）</td><td>3.7% CAGR</td></tr><tr><td>预测价值（2034F）</td><td>4.779亿美元</td></tr></tbody></table><p>类别洞察</p><table><thead><tr><th>属性</th><th>经导管主动脉瓣置换术（TAVR）</th></tr></thead><tbody><tr><td>细分市场价值（2024E）</td><td>49.4亿美元</td></tr><tr><td>增长率（2024年至2034年）</td><td>10.1% CAGR</td></tr><tr><td>预测价值（2034F）</td><td>129.6亿美元</td></tr></tbody></table><table><thead><tr><th>属性</th><th>医院</th></tr></thead><tbody><tr><td>市场价值（2024E）</td><td>45.6亿美元</td></tr><tr><td>增长率（2024年至2034年）</td><td>9.9% CAGR</td></tr><tr><td>预测价值（2034F）</td><td>116.8亿美元</td></tr></tbody></table>